Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Melanoma Combo Therapy

09/20/2021 | 08:00am EDT


ę MT Newswires 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
07:34aBRISTOL MYERS SQUIBB : Says Zeposia Gets Positive Recommendation From CHMP for Ulcerative ..
MT
07:00aBRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatmen..
BU
05:34aBristol Myers Squibb Gets CHMP Backing for Zeposia in Ulcerative Colitis
DJ
10/13BRISTOL MYERS SQUIBB : Announces Up to Five Years of Data from Long-Term DAYBREAK Study Re..
BU
10/13Bristol-Myers Squibb Company Announces Interim Results from the Phase 3 Open-Label Exte..
CI
10/12BRISTOL MYERS SQUIBB : Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $66 ..
MT
10/12AGENUS : to Receive $20 Million Payment from Bristol Myers Squibb for AGEN1777; Shares Up ..
MT
10/11EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include novel cel..
AQ
10/11EVOTEC : LUMITOS AG - Evotec expands neuroscience collaboration with Bristol Myers Squibb ..
AQ
10/08BRISTOL MYERS SQUIBB : Barclays Adjusts Bristol-Myers Squibb's PT to $68 from $71, Keeps E..
MT
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 360 M - -
Net income 2021 6 492 M - -
Net Debt 2021 28 452 M - -
P/E ratio 2021 20,0x
Yield 2021 3,41%
Capitalization 128 B 128 B -
EV / Sales 2021 3,38x
EV / Sales 2022 3,05x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 57,70 $
Average target price 74,73 $
Spread / Average Target 29,5%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.98%128 216
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.12.52%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579